125 related articles for article (PubMed ID: 28408354)
1. Therapeutic effects of Argyrin F in pancreatic adenocarcinoma.
Chen X; Bui KC; Barat S; Thi Nguyen ML; Bozko P; Sipos B; Kalesse M; Malek NP; Plentz RR
Cancer Lett; 2017 Jul; 399():20-28. PubMed ID: 28408354
[TBL] [Abstract][Full Text] [Related]
2. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma.
Soltek S; Karakhanova S; Golovastova M; D'Haese JG; Serba S; Nachtigall I; Philippov PP; Werner J; Bazhin AV
Naunyn Schmiedebergs Arch Pharmacol; 2015 Nov; 388(11):1121-8. PubMed ID: 26105003
[TBL] [Abstract][Full Text] [Related]
5. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling.
Duan W; Qian W; Zhou C; Cao J; Qin T; Xiao Y; Cheng L; Li J; Chen K; Li X; Ma J; Ma Q
Oncol Rep; 2018 Sep; 40(3):1495-1502. PubMed ID: 29956804
[TBL] [Abstract][Full Text] [Related]
6. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
7. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
[TBL] [Abstract][Full Text] [Related]
8. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells.
Nagathihalli NS; Castellanos JA; VanSaun MN; Dai X; Ambrose M; Guo Q; Xiong Y; Merchant NB
Oncotarget; 2016 Oct; 7(40):65982-65992. PubMed ID: 27602757
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2 in pancreatic ductal adenocarcinoma.
Yang J; Dong Z; Ren A; Fu G; Zhang K; Li C; Wang X; Cui H
J Cell Mol Med; 2020 Apr; 24(7):4245-4260. PubMed ID: 32141702
[TBL] [Abstract][Full Text] [Related]
11. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.
Nickeleit I; Zender S; Sasse F; Geffers R; Brandes G; Sörensen I; Steinmetz H; Kubicka S; Carlomagno T; Menche D; Gütgemann I; Buer J; Gossler A; Manns MP; Kalesse M; Frank R; Malek NP
Cancer Cell; 2008 Jul; 14(1):23-35. PubMed ID: 18598941
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Zhu X; Chen X; Li C; Zong G; Zhou G; Wan C
Hum Pathol; 2016 Nov; 57():182-192. PubMed ID: 27498060
[TBL] [Abstract][Full Text] [Related]
13. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.
Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Gieseler F; Ungefroren H
Mol Cancer; 2015 Nov; 14():199. PubMed ID: 26588899
[TBL] [Abstract][Full Text] [Related]
16. δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis.
Husain K; Centeno BA; Coppola D; Trevino J; Sebti SM; Malafa MP
Oncotarget; 2017 May; 8(19):31554-31567. PubMed ID: 28404939
[TBL] [Abstract][Full Text] [Related]
17. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.
Arensman MD; Telesca D; Lay AR; Kershaw KM; Wu N; Donahue TR; Dawson DW
Mol Cancer Ther; 2014 Oct; 13(10):2303-14. PubMed ID: 25082960
[TBL] [Abstract][Full Text] [Related]
18. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism.
Zhu H; Xiao Y; Guo H; Guo Y; Huang Y; Shan Y; Bai Y; Lin X; Lu H
Aging (Albany NY); 2021 Dec; 13(23):25089-25105. PubMed ID: 34863080
[TBL] [Abstract][Full Text] [Related]
19. Elevation of β-galactoside α2,6-sialyltransferase 1 in a fructoseresponsive manner promotes pancreatic cancer metastasis.
Hsieh CC; Shyr YM; Liao WY; Chen TH; Wang SE; Lu PC; Lin PY; Chen YB; Mao WY; Han HY; Hsiao M; Yang WB; Li WS; Sher YP; Shen CN
Oncotarget; 2017 Jan; 8(5):7691-7709. PubMed ID: 28032597
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
